论文部分内容阅读
选取2014年6月~2015年12月于我院诊断为2型糖尿病的患者65例,随机分为实验组(n=33)和对照组(n=32),对照组采用二甲双胍治疗,实验组采用西格列汀与二甲双胍联合治疗。3个月后检测分析两组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2h PG)、糖化血红蛋白(HbA_(1c))、体重指数(BMI)、空腹C肽(FCP)、餐后2hC肽(2hCP)值的变化和两组患者治疗后不良反应发生率。结果治疗前,两组患者的FBG、2h PG、Hb A_(1c)、BMI、FCP、2 hCP水平之间差异不明显,无统计学意义(P>0.05)。经过治疗后,两组患者的FBG、2h PG、HbA_(1c)、BMI、FCP、2hCP水平均有所下降,实验者患者下降更为明显,两组数据差异显著,有统计学意义(P<0.05)。用药后不良反应比例差异不明显,无统计学意义(P<0.05)。结论西格列汀与二甲双胍联合治疗对2型糖尿病有显著疗效,且无不良反应,值得临床推广。
Sixty-five patients diagnosed with type 2 diabetes mellitus in our hospital from June 2014 to December 2015 were randomly divided into experimental group (n = 33) and control group (n = 32), the control group was treated with metformin, and the experimental group The combination of sitagliptin and metformin was used. After 3 months, the levels of fasting blood glucose (FBG), 2h PG, HbA 1c, BMI, FCP, 2hC peptide (2hCP) value changes and two groups of patients after treatment, the incidence of adverse reactions. Results Before treatment, there was no significant difference between the two groups in the FBG, 2h PG, Hb A 1c, BMI, FCP and 2 hCP levels (P> 0.05). After treatment, the levels of FBG, 2h PG, HbA 1c, BMI, FCP and 2hCP decreased in both groups, and the decline in the experimental group was more obvious. The difference between the two groups was statistically significant (P < 0.05). There was no significant difference in the proportion of adverse reactions after treatment (P <0.05). Conclusion The combination of sitagliptin and metformin has a significant effect on type 2 diabetes mellitus, and no adverse reactions, worthy of clinical promotion.